Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2

Comparative Biochemistry and Physiology - C Toxicology and Pharmacology

Volumn 143, Issue 4, 2006, Pages 429-435

  Xie, Weidong ^a   Wang, Wei ^a   Su, Hui ^a   Xing, Dongming ^a   Pan, Yang ^a   Du, Lijun ^a  

^a TSINGHUA UNIVERSITY   (China)

Author keywords

Ananas comosus L.; Fenofibrate; Glycogen; High fat diets; Insulin resistance; Metformin; Pineapple; Tolbutamide; Type 2 diabetes

Indexed keywords

ALLOXAN; ANASAS COMOSUS EXTRACT; ANTIDIABETIC AGENT; FENOFIBRATE; GLUCOSE; INSULIN; METFORMIN; PLANT EXTRACT; TOLBUTAMIDE; UNCLASSIFIED DRUG;

ANANAS COMOSUS; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; DRUG EFFECT; DYSLIPIDEMIA; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; MALE; MEDICINAL PLANT; NONHUMAN; PLANT LEAF; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES;

ANANAS COMOSUS; ANIMALIA; RATTUS NORVEGICUS;

EID: 33746084454     PISSN: 15320456     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cbpc.2006.04.002     Document Type: Article

References (31)

1. Bailey C.J. Metformin-an update. Gen. Pharmacol. 24 (1993) 1299-1309
2. Chang S.L., Lin J.G., Chi T.C., Liu I.M., and Cheng J.T. An insulin-dependent hypoglycaemia induced by electroacupuncture at the Zhongwan (CV12) acupoint in diabetic rats. Diabetologia 42 (1999) 250-255
3. Chen D., and Wang M.W. Development and application of rodent models for type 2 diabetes. Diabetes Obes. Metab. 7 (2005) 307-317
4. Chi J.T., Liu I.M., and Cheng J.T. A simple and rapid model of insulin-resistance in Wistar rats. Chin. Pharm. J. 50 (1998) 113-121
5. Cordain L., Eades M.R., and Eades M.D. Hyperinsulinemic diseases of civilization: more than just Syndrome X. Comp. Biochem. Physiol., A 136 (2003) 95-112
6. Damci T., Tatliagac S., Osar Z., and Ilkova H. Fenofibrate treatment is associated with better glycemic control and lower serum leptin and insulin levels in type 2 diabetic patients with hypertriglyceridemia. Eur. J. Intern. Med. 14 (2003) 357-360
7. Egger M., Davey S.G., Stettler C., and Diem P. Risk of adverse effects of intensified treatment in insulin-dependent diabetes mellitus: a meta-analysis. Diabet. Med. 14 (1997) 919-928
8. Fanger B.O. Adaptation of the Bradford protein assay to membrane-bound proteins by solubilizing in glucopyranoside detergents. Anal. Biochem. 162 (1987) 11-17
9. Forman L.M., Simmons D.A., and Diamond R.H. Ann. Intern. Med. 132 (2000) 118-121
10. Gomez-Lechon M.J., Ponsoda X., and Castell J.V. A microassay for measuring glycogen in 96-well-cultured cells. Anal. Biochem. 236 (1996) 296-301
11. Hermayer K.L. Treatment of lipids and type 2 diabetes. Curr. Cardiol. Rep. 6 (2004) 443-450
12. Kopelman P. The metabolic syndrome as a clinical problem. Nestle Nutr. Workshop Ser. Clin. Perform. Progr. 9 (2004) 77-88 (discussion 88-92)
13. Kordowiak A.M., Dudek B., and Grybos R. Influence of sodium bis(oxalato)oxovanadate(IV) on phospholipids in liver Golgi fractions from control and streptozotocin-diabetic rats. Comp. Biochem. Physiol., C 125 (2000) 11-16
14. Li C.G., Ning G., and Chen J.L. Establishing and identifying insulin-resistant HepG2 cell line. Chin. Diabetes 7 (1999) 198-200 (in Chinese)
15. Mensah G.A., Mokdad A.H., Ford E., Narayan K.M., Giles W.H., Vinicor F., and Deedwania P.C. Obesity, metabolic syndrome, and type 2 diabetes: emerging epidemics and their cardiovascular implications. Cardiol. Clin. 22 (2004) 485-504
16. Milani E., Nikfar S., Khorasani R., Zamani M.J., and Abdollahi M. Reduction of diabetes-induced oxidative stress by phosphodiesterase inhibitors in rats. Comp. Biochem. Physiol., C 140 (2005) 251-255
17. Reed M.J., Meszaros K., Entes L.J., Claypool M.D., Pinkett J.G., Gadbois T.M., and Reaven G.M. A new rat model of type 2 diabetes: the fat-fed, streptozotocin-treated rat. Metabolism 49 (2000) 1390-1394
18. Rett K. The relation between insulin resistance and cardiovascular complications of the insulin resistance syndrome. Diabetes Obes. Metab. 1 (1999) S8-S16
19. Pari L., and Saravanan G. Antidiabetic effect of Cogent db, a herbal drug in alloxan-induced diabetes mellitus. Comp. Biochem. Physiol., C 131 (2002) 19-25
20. Scheen A.J. Management of the metabolic syndrome. Minerva Endocrinol. 29 2 (2004) 31-45
21. Scheen A.J., and Lefebvre P.J. Troglitazone: andtihyperglycemic activity and potential role in the treatment of type 2 diabetes. Diabetes Care 22 (1999) 1568-1577
22. Song L.L. Chinese Herbs. Administrant Department of National Chinese Traditional Medicine, Shang Hai, chapter 8 (1999) 296-297 (in Chinese)
23. Sripanidkulchai B., Na-nakorn S., Wongpanich V., and Tanyakupta P. A behavioral investigation on utilization of medicinal plants for dysuria at Pon District, Khon Kaen. Khon Kaen University Research Journal vol. 5 (2000) 4-10
24. Sripanidkulchai B., Wongpanich V., Laupattarakasem P., Suwansaksri J., and Jirakulsomchok D. Diuretic effects of selected Thai indigenous medicinal plants in rats. J. Ethnopharmacol. 75 (2001) 185-190
25. Trevaskis J., McMillan J.S., Windmill K., Walder K., and Collier G.R. Identification of hypothalamic genes implicated in the development of obesity in Psammomys obesus using differential display PCR. Comp. Biochem. Physiol., B 137 (2004) 65-73
26. Wu Y.C., Hsu J.H., Liu I., Liou S.S., Su H.C., and Cheng J.T. Increase of insulin sensitivity in diabetic rats received Die-Huang-Wan, a herbal mixture used in Chinese traditional medicine. Acta Pharmacol. Sin. 23 12 (2002) 1181-1187
27. Xie W.D., and Du L.J. High-cholesterol diets impair short-term retention of memory in alloxan-induced diabetic mice, but not acquisition of memory in prediabetic mice. Life Sci. 77 (2005) 481-495
28. Xie W.D., Xing D.M., Sun H., Wang W., Ding Y., and Du L.J. The effects of Ananas comosus L. leaves on diabetic-dyslipidemic rats induced by alloxan and a high-fat/high-cholesterol diet. Am. J. Chin. Med. 33 (2005) 95-105
29. Xie W.D., Xing D.M., Zhao Y.N., Su H., Meng Z., Chen Y.Y., and Du L.J. A new tactic to treat postprandial hyperlipidemia in diabetic rats with gastroparesis by improving gastrointestinal transit. Eur. J. Pharmacol. 510 (2005) 113-120
30. Xu J.S., Ma M.W., and Purcell W.M. Characterisation of some cytotoxic endpoints using rat liver and HepG2 spheroids as in vitro models and their application in hepatotoxicity studies. I. Glucose metabolism and enzyme release as cytotoxic markers. Toxicol. Appl. Pharmacol. 189 (2003) 100-111
31. Zhang F., Ye C., Li G., Ding W., Zhou W., Zhu H., Chen G., Luo T., Guang M., Liu Y., Zhang D., Zheng S., Yang J., Gu Y., Xie X., and Luo M. The rat model of type 2 diabetic mellitus and its glycometabolism characters. Exp. Anim. 52 (2003) 401-407